Cell death regulation by B-cell lymphoma protein

Apoptosis

Volumn 11, Issue 4, 2006, Pages 459-471

  Verma, Y K ^a   Gangenahalli, G U ^a,c   Singh, V K ^a   Gupta, P ^a   Chandra, R ^b   Sharma, R K ^c   Raj, H G ^d  

^a Stem Cell Gene Therapy Research Group   (India)

^b UNIVERSITY OF DELHI   (India)

^c INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^d UNIVERSITY OF DELHI   (India)

Author keywords

Active site; Bcl 2 family; Hematopoietic stem cells; Homology model; Inducible expression; Mutants

Indexed keywords

B CELL LYMPHOMA PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; MUTANT PROTEIN; PROTEIN BCL 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; FOLLICULAR LYMPHOMA; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO STUDY; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN INTERACTION; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS; STRESS; TRANSCRIPTION REGULATION; TRANSLATION REGULATION;

ANIMALS; APOPTOSIS; CASPASE 9; CASPASES; GENE EXPRESSION REGULATION; MUTATION; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 33646395652     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-006-5702-1     Document Type: Article

References (100)

1. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for Bcl-2 and a hybrid Bcl-2/immunoglobulin transcript resulting from the t (14;18) translocation. Cell 1986; 47: 19-28.
2. Reed JC. Bcl-2 and the regulation of programmed cell death. J. Cell Biol 1994; 124: 1-6.
3. Adams JM, Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 1998; 281: 1322-1326.
4. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281(5381): 1309-1312.
5. Gross A, McDonnell JM, Korsmeyer SJ. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899-1911.
6. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999; 15: 269-290.
7. Heiden VMG, Thompson CB. Bcl-2 proteins: Regulators of apoptosis or of mitochondrial homeostasis? Nat Cell Biol 1999; 1(8): E209-E216.
8. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-776.
9. Strasser A, O'Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem 2000; 69: 217-245.
10. Borner C, Martinou I, Mattmann C. The protein Bcl-2α does not require membrane attachment, but two conserved domains to suppress apoptosis. J Cell Biol 1994; 126: 1059-1068.
11. Yang X, Tang SC, Pater A. Cloning and characterization of human BAG-1 gene promoter: Upregulation by tumor-derived p 53 mutants. Oncogene 1999; 18: 4546-4553.
12. Naumouski L, Cleary ML. The p53 binding protein 53BP2 also interacts with Bcl-2 and impedes cell cycle progression at G2/M. Mol Cell Biol 1996; 16(7): 3884-3892.
13. Deng X, Ito T, Carr B, Mumby M, May Jr. WS Reversible phosphorylation of Bcl-2 following interleukin 3 or bryostatin 1 is mediated by direct interaction with protein phosphatase 2A. J Biol Chem 1998; 273: 34157-34163.
14. Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997; 387: 773-776.
15. Cheng EH, Kirsch DG, Clem RJ. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 1997; 278: 1966-1968.
16. Bryan WJ, Lawrence HB. Bcl-2 and caspase inhibition cooperate to inhibit tumor necrosis factor-α-induced cell death in a Bcl-2 cleavage-independent fashion. J Biol Chem 1999; 274(26): 18552-18558.
17. L through caspase interaction. PNAS USA 1998; 95: 554-559.
18. Nicholson DW, Thornberry NA. Caspases: Killer proteases. Trends Biochem Sci 1997; 22: 299-306.
19. Dimmler S, Breitschopf K, Haendeler J, Zeiher AM. Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: A link between the apoptosome and the proteosome pathway. J Exp Med 1999; 189(11): 1815-1822.
20. Ruvolo PP, Deng X, Ito T, Carr BK, May WS. Ceramide induces Bcl-2 dephosphorylation via a mechanism involving mitochondrial PP2A. J Biol Chem 1999; 274(29): 20296-20300.
21. Shibasaki F, Kondo E, Akagi T, Mckeon F. Suppression of signaling through transcription factor NFAT by interaction between calcineurin and Bcl-2. Nature 1997; 386: 728-731.
22. Domen J, Weissman I. Self-renewal, differentiation or death: Regulation and manipulation of hematopoietic stem cell fate. Molecular Medicine Today 1999; 5(5): 201-208.
23. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75: 241-251.
24. Baffy G, Miyashita T, Williamson Jr. Apoptosis induced by withdrawal of interleukin-3 (IL-3) from an IL-3-dependent hematopoietic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production. J Biol Chem 1993; 268(9): 6511-6519.
25. Marchetti P. Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 1996; 184:1155-1160.
26. Shimizu S, Konishi A, Kodama T, Tsujimoto Y. BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. PNAS USA 2000; 97: 3100-3105.
27. L, an inhibitor of programmed cell death. Nature 1996; 381: 335-341.
28. Antonsson B, Conti F, Ciavatta AM, et al. Inhibition of Bax channel-forming activity by Bcl-2. Science 1997; 277(5324): 370-372.
29. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999; 397: 441-446.
30. Thomenius MJ, Distelhorst CW. Bcl-2 on the endoplasmic reticulum: Protecting the mitochondria from a distance. J Cell Sci 2003; 116: 4493-4499.
31. -/- mice. Cell 1997; 89: 1011-1019.
32. Lang G, Gombert WM, Gould HJ. A transcriptional element in the coding sequence of the human Bcl-2 gene. Immunology 2005; 114: 25-36.
33. Seto M, Jaeger U, Hockett RD, et al. Alternative promoter and exons, somatic mutations and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J 1988; 7: 123-131.
34. Nunez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hematopoietic cell lines. J Immunol 1990; 144: 3602-3610.
35. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of Bcl-2, the gene involved in human follicular lymphoma. PNAS USA 1986; 83: 5214-5218.
36. Batistatou A, Merry DE, Korsmeyer SJ, Greene LA. Bcl-2 affects survival but not neuronal differentiation of PC12 cells. J Neurosci 1993; 13: 4422-4428.
37. Wilson BE, Mochon E, Boxer LM. Induction of Bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol 1996; 16: 5546-5556.
38. Dong L, Wang W, Wang F, et al. Mechanisms of transcriptional activation of Bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J Biol Chem 1999; 274(45): 32099-32107.
39. Li ZL, Abe H, Ueki K, Kumagai K, Araki R, Otsuki Y. Identification of c-Jun as Bcl-2 transcription factor in human uterine endometrium. J Histochem Cytochem 2003; 51(12): 1601-1609.
40. Otsuki Y, Misaki O, Sugimoto O, Ito Y, Tsujimoto Y, Akao Y. Cyclic Bcl-2 gene expression in human uterine endometrium during menstrual cycle. Lancet 1994; 344: 28-29.
41. Savill J, Mooney A, Hughes J. What role does apoptosis play in progression of renal disease? Curr Opin Nephrol Hypertens 1996; 5(4): 369-374.
42. Young RL, Korsmeyer SJ. A negative regulatory element in the Bcl-2 5′-untranslated region inhibits expression from an upstream promoter. Mol Cell Biol 1993; 13(6): 3686-3697.
43. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the Bcl-2 gene. Cancer Res 1994a; 54: 3131-3135.
44. Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of Bcl-2 and Bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-1805.
45. Schiavone I, Rosini P, Quattrone A, Donnini M, Lapucci A, Citti L. A conserved AU-rich element in the 3′ untranslated region of Bcl-2 mRNA is endowed with a destabilizing function that is involved in Bcl-2 down-regulation during apoptosis. The FASEB Journal 2000; 14: 174-184.
46. Chen-Levy Z, Nourse J, Cleary ML. The Bcl -2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol Cell Biol 1989; 9: 701-710.
47. Petros AM, Olejniczak ET, Fesik SW. Structural biology of the Bcl-2 family of proteins. Biochimica et Biophysica Acta. Molecul Cell Research 2004; 1644: 83-94.
48. L/Bak peptide complex: Recognition between regulators of apoptosis. Science 1997; 275: 983-986.
49. Gurudutta GU, Verma YK, Singh VK, et al. Structural conservation of residues in BH1 and BH2 domains of Bcl-2 family proteins. FEBS Lett 2005 Jul 4; 579(17): 3503-3507.
50. Borner C. Dissection of functional domains in Bcl-2α by site-directed mutagenesis. Biochem Cell Biol 1994; 72: 463-469.
51. Diaz JL. A common binding site mediates heterodimerization and homodimerization of Bcl-2 family members. J Biol Chem 1996; 272(17): 11350-11355.
52. L-Bak peptide complex: Recognition between regulators of apoptosis. Science 1997; 275: 983-986.
53. Zha H. Heterodimerization independent functions of cell death regulatory proteins Bax and Bcl-2 in yeast and mammalian cells. J Biol Chem 1997; 272: 31482-31488.
54. Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996; 87: 629-638.
55. Wang HG, Takayama S, Rapp UR, Reed JC. Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. PNAS USA 1996; 93: 7063-7068.
56. Pietenpol JA, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B. Paradoxical inhibition of solid tumor cell growth by Bcl-2. Cancer Res 1994; 54: 3714-3717.
57. Linette GP, Li Y, Roth K, Korsmeyer SJ. Cross talk between cell death and cell cycle progression: Bcl-2 regulates NFAT-mediated activation. PNAS USA 1996; 93: 9545-9552.
58. Müller C, Kowenz-Leutz E, Grieser-Ade S, Graf T, Leutz A. NF-M (chicken C/EBPb) induces eosinophilic differentiation and apoptosis in a hematopoietic progenitor cell line. EMBO J 1995; 14: 6127-6135.
59. Zhang J, Alter N, Reed JC, Borner C, Obeid LM, Hannun YA. Bcl-2 interrupts the ceramide-mediated pathway of cell death. Biochemistry 1996; 93(11): 5325-5328.
60. L and Bcl-2. EMBO J 1997; 16: 968-977.
61. Petros AM, Medek A, Nettesheim DG, Kim DH, Yoon HS, Swift K, et al. Solution structure of the antiapoptotic protein Bcl-2. PNAS USA 2001; 98(6): 3012-3017.
62. L/Bim fragment complex: Implications for Bim function. Immunity 2003; 19: 341-352.
63. Fesik SW. Insight into programmed cell death through structural biology. Cell 2000; 103: 273-282.
64. Huang Q. Solution structure of the BHRF1 protein from Epstein-Barr virus, a homolog of human Bcl-2. J Mol Biol 2003; 332: 1123-1130.
65. Peitsch MC. ProMod and Swiss-Model: Internet-based tools for automated comparative p rotein modelling. Biochem Soc Trans 1996; 24: 274-279.
66. Verma YK, Gurudutta GU, Singh VK, et al. Homology model of anti-apoptotic protein Bcl-2. Bioinformatics India 2006; 3(3): in press.
67. Day CL, Puthalakath H, Skea G, et al. Localization of dynein light chains 1 and 2 and their pro-apoptotic ligands. Biochem J 2004; 377(3): 597-605.
68. Antonsson B, Martinou JC. The Bcl-2 protein family. Exp Cell Res 2000; 256: 50-57.
69. Yamamoto K, Ichijo H, Korsmeyer SJ. Bcl-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G2/M. Molecul Cellular Biol 1999; 19(12): 8469-8478.
70. Ruvolo PP, Deng X, May WS Jr. Phosphorylation of Bcl-2 and regulation of apoptosis. Leukemia 2001; 15: 515-522.
71. Meier P, Finch A, Evan G. Apoptosis in development. Nature 2000; 407: 796-801.
72. McDonnell JM, Fushman D, Milliman CL, Korsmeyer SJ, Cowburn D. Solution structure of the proapoptotic molecule BID: a structural basis for apoptotic agonists and antagonists. Cell 1999; 96: 625-634.
73. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. PNAS USA 1995; 92: 4507-4511.
74. Haldar S, Chintapalli J, Croce CM. Taxol induces Bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56: 1253-1255.
75. Haldar S, Basu A, Croce CM. Serine-70 is one of the critical sites for drug-induced Bcl-2 phosphorylation in cancer cells. Cancer Res 1998; 58: 1609-1615.
76. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 1996; 56: 1851-1854.
77. Blagosklonny MV, Giannakakou P, El-Deiry WS, et al. Raf-1/Bcl-2 phosphorylation: A step from microtubule damage to cell death. Cancer Res 57: 130-135.
78. Blagosklonny MV, Chuman Y, Bergan RC, Fojo T. Mitogen activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells. Leukemia 1999; 13: 1028-1036.
79. Hannun YA. The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem 1994; 269: 3125-3128.
80. Jarvis WD, Grant S, Kolesnick RN. Ceramide and the induction of apoptosis. Clin Cancer Res 1996; 2: 1-6.
81. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995; 376: 37-43.
82. Johnson BW, Boise LH. Bcl-2 and caspase inhibition cooperate to inhibit tumor necrosis factor-induced cell death in a Bcl-2 cleavage-independent fashion. J Biol Chem 1999; 274(26): 18552-18558.
83. Russel JH, Rush B, Weaver C, Wang R. Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. PNAS USA 1993; 90: 4409-4413.
84. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995; 14: 5579-5588.
85. Johnson BW, Boise LH. Bcl-2 and caspase inhibitor (zVAD-fmk) cooperate to inhibit tumor necrosis factor-α-induced cell death in a Bcl-2 cleavage independent fashion. J Biol Chem 1999; 274(26): 18552-18558.
86. L. Nature 1996; 379: 554-556.
87. Cheng EHY, Nicholas J, Bellows DS, Hayward GS, Guo HG, Reitz MS, et al. A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. PNAS USA 1997; 94: 690-694.
88. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes hamatopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-442.
89. Lagasse E, Weissman IL. Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice. Cell 1997; 89(7): 1021-1031.
90. -/- mice. Cell 1997; 89: 1011-1019.
91. Reed JC. Mechanisms of Bcl-2 family protein function and dysfunction in health and disease. Behring Inst Mit 1996; 97: 72-100.
92. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124: 619-626.
93. Domen J, Gandy KL. Systemic overexpression of Bcl-2 in the hematopoietic system protects transgenic mice from the consequences of lethal irradiation. Blood 1998; 91: 2272-2282.
94. Tsukasaki K, Tsushima H, Yamamura M, et al. Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: Frequent clonal change at crisis from indolent disease. Blood 1997; 89(3): 948-956.
95. Huang HM, Li JC, Hsieh YC, Yen HFY, Yen JJY. Optimal proliferation of a hematopoietic progenitor cell line requires either costimulation with stem cell factor or increase of receptor expression that can be replaced by overexpression of Bcl-2. Blood 1999; 93(8): 2569-2577.
96. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. PNAS USA 1992; 89(12): 5547-5551.
97. Francis K, Ramakrishna R, Holloway W, Palsson BO. Two new pseudopod morphologies displayed by the human hematopoietic kG-1a progenitor cell line and by primary human CD34 cells. Blood 1998; 92(10): 3616-3623.
98. Wyllie AH. The genetic regulation of apoptosis. Curr Opin Gen Dev 1995; 5: 97-104.
99. Deng X, Ruvolo P, Carr B, May Jr WS. Survival function of ERk1/2 as IL-3 activated, staurosporine-resistant Bcl-2 kinases. PNAS USA 2000; 97(4): 1578-1583.
100. Rao S, Watkins S, Cunningham D, et al. Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma. Ann Oncol 1997; 15: 1413-1418.